The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Plexxikon (I)
Stock and Other Ownership Interests - Merck
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.
 
Zev A. Wainberg
Consulting or Advisory Role - Sirtex Medical; Taiho Pharmaceutical
Speakers' Bureau - Genentech
Research Funding - Biomarin (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech; Lilly
 
Peter D. Eisenberg
No Relationships to Disclose
 
Jasgit C. Sachdev
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Research Funding - Celgene (Inst); Pfizer (Inst)
 
Amy M. Weise
No Relationships to Disclose
 
David Ross Kaufman
Employment - Merck
 
Marguerite Hutchinson
Employment - Plexxikon
 
Sandra Tong
No Relationships to Disclose
 
Ireene Aromin
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Siwen Hu-Lieskovan
No Relationships to Disclose
 
Amita Patnaik
Research Funding - Merck (Inst)